Provention Bio inks China deal for autoimmune program; Kyowa Kirin releases positive topline data in atopic dermatitis
Provention Bio is making its way into China with a new deal announced Wednesday.
The Red Bank, NJ-based biotech has agreed to a deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, in China, Hong Kong, Macau and Taiwan. Provention will get $6 million upfront and up to $11.5 million in funding over the next three years to cover expected research costs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters